Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis

To date, no head-to-head trials have compared the efficacy of brigatinib and alectinib against anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p), ALK-inhibitor-naïve, advanced non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. We conducted an indirect trea...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Ando, Koichi, Akimoto, Kaho, Sato, Hiroki, Manabe, Ryo, Kishino, Yasunari, Homma, Tetsuya, Kusumoto, Sojiro, Yamaoka, Toshimitsu, Tanaka, Akihiko, Ohmori, Tohru, Sagara, Hironori
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226463/
https://ncbi.nlm.nih.gov/pubmed/32290309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040942
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires